Investigating new dermatological medications

CRS has extensive experience in conducting early phase clinical trials in the field of dermatology from planning to completion and with reliable results. These specifically include first-in-human (FiH) clinical trials and studies with challenging techniques and invasive procedures, which require special expertise and practical experience.

CRS – competent partner for your dermatological product development

CRS, in particular the CRS Berlin and the CRS Kiel units, currently conducts approximately one to three clinical trials per year investigating new dermatological medications. In recent years, CRS Kiel has also successfully completed most sophisticated clinical trials including first-in-human testing of biologicals and, among others, blister induction and aspiration. All this is attributed to the advanced level of expertise and experience of the CRS Kiel team, including Abir Alatrach, MD, CRS in-house dermatologist. In addition, it is planned to conduct further studies in the field of dermatology in the modern and newly opened facilities of the CRS Berlin unit.

CRS has particular recruitment capabilities, which are supported by a well-established and long-standing collaboration with a network of external dermatologists, with large outpatient departments, and with specialists at the dermatology department of the university hospital in Kiel. CRS proprietary database allows easy identification and rapid recruitment of volunteers, patients, as well as matched elderly controls for all kind of clinical trials in the field of dermatology.

The local medical lab partner of CRS Kiel, LKF – Laboratorium für Klinische Forschung GmbH, which is specialized and accredited for the support of clinical trials, secures a reliable and rapid turnaround of laboratory results, most of which will be supplied within six hours. This facilitates screening and review of inclusion/exclusion criteria, as well as close safety monitoring of trial participants.

Dermatological assessment techniques employed at CRS

  • Scoring Atopic Dermatitis (SCORAD)
  • Psoriasis Skin Severity Index (PASI)
  • Overall Lesion Severity (OLS)
  • Irritation, sensitisation of topical and transdermal application systems
  • Skin biopsies
  • Subcutaneous adipose tissue biopsies
  • Blister induction and aspiration
  • Skin prick test for immediate allergic reactions – type I hypersensitivity
  • Eczema Area and Severity Index (EASI Score)


Martin Mulder

Senior Vice President Corporate & Business Development



CRO Leadership Awards 2019

CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability.

European Biotechnology Guide

Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019.

EcoVadis – CSR Rating

Based on the CSR rating by EcoVadis in 2022 CRS has been granted Silver Recognition Level.